Ubs Asset Management Americas Inc Fibrogen Inc Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $45,824 - $72,342	2,873 Added 2.81%	105,083 $1.96 Million
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $274,118 - $366,248	20,657 Added 25.33%	102,210 $1.64 Million
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $68,616 - $87,877	-6,019 Reduced 6.87%	81,553 $1.06 Million
Q2 2022 Aug 12, 2022	SELL	$7.94 - $12.96 $21,565 - $35,199	-2,716 Reduced 3.01%	87,572 $924,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.79 $235,640 - $329,151	19,604 Added 27.73%	90,288 $1.09 Million
Q4 2021 Feb 14, 2022	SELL	$9.93 - $15.39 $133,260 - $206,533	-13,420 Reduced 15.96%	70,684 $996,000
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $18,883 - $49,417	1,855 Added 2.26%	84,104 $859,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $232,849 - $447,391	-12,539 Reduced 13.23%	82,249 $2.19 Million
Q1 2021 May 14, 2021	BUY	$31.0 - $55.72 $4,495 - $8,079	145 Added 0.15%	94,788 $3.29 Million
Q4 2020 Mar 01, 2021	BUY	$37.09 - $48.97 $234,112 - $309,098	6,312 Added 7.15%	94,643 $3.51 Million
Q3 2020 Nov 13, 2020	BUY	$40.47 - $45.5 $549,744 - $618,072	13,584 Added 18.17%	88,331 $3.63 Million
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $75,953 - $99,879	-2,332 Reduced 3.03%	74,747 $3.03 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $5.44 Million - $10.7 Million	-233,635 Reduced 75.19%	77,079 $2.68 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $449 - $624	-13 Reduced -0.0%	310,714 $13.3 Million
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $586,946 - $768,998	15,872 Added 5.38%	310,727 $11.5 Million
Q2 2019 Aug 15, 2019	SELL	$35.13 - $55.53 $2.12 Million - $3.36 Million	-60,418 Reduced 17.01%	294,855 $0
Q1 2019 May 14, 2019	SELL	$42.83 - $59.91 $243,488 - $340,588	-5,685 Reduced 1.57%	355,273 $0
Q4 2018 Feb 13, 2019	BUY	$37.97 - $60.16 $4.95 Million - $7.85 Million	130,405 Added 56.56%	360,958 $16.7 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $467,909 - $558,914	-8,311 Reduced 3.48%	230,553 $0
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $609,562 - $881,761	-13,576 Reduced 5.38%	238,864 $0
Q1 2018 May 14, 2018	SELL	$45.35 - $61.65 $228,790 - $311,024	-5,045 Reduced 1.96%	252,440 $0
Q4 2017 Feb 09, 2018	BUY	$41.95 - $60.1 $1.68 Million - $2.41 Million	40,113 Added 18.45%	257,485 $0
Q3 2017 Nov 13, 2017	BUY	$33.4 - $53.9 $7.26 Million - $11.7 Million	217,372	217,372 $0

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account